JAK Inhibitors in the Management of Atopic Dermatitis | videos

Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.

Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.

Drs Alexandra Golant and Brett King discuss the role that atopic disease severity and treatment resistance play in the selection of oral vs systemic treatment for their patients.

Brett King, M.D, Ph.D and Alexandra Golant M.D comment on their considerations on the management of patients suffering from atopic dermatitis, highlighting the importance of body surface area and patient preference in treatment selection.

Drs Raj Chovatiya and Neal Bhatia summarize their final thoughts on the available treatment options for the management of atopic dermatitis.

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Experts in dermatology discuss the use of oral and topical JAK inhibitors in clinical practice and their reflection of overarching treatment guidelines and indications.

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.